Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor (original) (raw)

References

  1. Allavena P, Sica A, Solinas G, Porta C, Mantovani A . The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 2007 [e-pub ahead of print].
  2. Pollard JW . Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71–78.
    Article CAS Google Scholar
  3. Muller AJ, Scherle PA . Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006; 6: 613–625.
    Article CAS Google Scholar
  4. Wiktor-Jedrzejczak W, Bartocci A, Ferrante Jr AW, Ahmed-Ansari A, Sell KW, Pollard JW et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 1990; 87: 4828–4832.
    Article CAS Google Scholar
  5. Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER . The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 1985; 41: 665–676.
    Article CAS Google Scholar
  6. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA 2005; 102: 16078–16083.
    Article CAS Google Scholar
  7. Irvine KM, Burns CJ, Wilks AF, Su S, Hume DA, Sweet MJ . A CSF-1 receptor kinase inhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations. FASEB J 2006; 20: 1921–1923.
    Article CAS Google Scholar
  8. Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther 2006; 5: 2634–2643.
    Article CAS Google Scholar
  9. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127–3132.
    Article CAS Google Scholar
  10. Taylor JR, Brownlow N, Domin J, Dibb NJ . FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 2006; 25: 147–151.
    Article CAS Google Scholar
  11. Kitaura H, Zhou P, Kim HJ, Novack DV, Ross FP, Teitelbaum SL . M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005; 115: 3418–3427.
    Article CAS Google Scholar
  12. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of _N_-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661.
    Article CAS Google Scholar
  13. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401.
    Article CAS Google Scholar
  14. Fabian MA, Biggs III WH, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG et al. A small molecule–kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329–336.
    Article CAS Google Scholar
  15. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541.
    Article CAS Google Scholar
  16. Dibb NJ, Dilworth SM, Mol CD . Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 2004; 4: 718–727.
    Article CAS Google Scholar
  17. Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473–481.
    Article CAS Google Scholar
  18. Milliken D, Scotton C, Raju S, Balkwill F, Wilson J . Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002; 8: 1108–1114.
    CAS PubMed Google Scholar
  19. Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O et al. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 2005; 19: 228–230.
    Article CAS Google Scholar
  20. Walter M, Lucet IS, Patel O, Broughton SE, Bamert R, Williams NK et al. The 2.7 Å crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol 2007; 367: 839–847.
    Article CAS Google Scholar
  21. Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790–5797.
    Article CAS Google Scholar
  22. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354: 2006–2013.
    Article CAS Google Scholar
  23. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM et al. Long term imatinib therapy promotes bone formation in CML patients. Blood 2007 [e-pub ahead of print].
  24. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP . Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008; 111: 4415–4416.
    Article CAS Google Scholar
  25. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366–1377.
    Article CAS Google Scholar

Download references